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2017 Scale-up and Manufacturing of Cell-Based Therapies Award Winner 
Sponsored by Pfizer and ECI 
 




Peter Zandstra has demonstrated outstanding achievements in elucidating the factors 
that regulate stem cell expansion and differentiation. He has also developed a 
fundamental understanding of the design principles for stem cell bioreactor technologies 
during nearly two decades at the University of Toronto. Peter’s work integrates 
engineering and biological approaches, and he has contributed to the development of 
clinically and industrially relevant and academically recognized technologies based on 
the design of bioprocesses for the growth and differentiation of adult and pluripotent 
stem cells. Key contributions include: 
 
• High-throughput experimental assays for determining molecular regulators of stem cell 
behavior 
 
• Conceptual and computational models for molecular regulation of stem cell 
proliferation and differentiation 
 
• Establishing bioreactor conditions to effectively yield desired stem cell proliferation and 
differentiation behavior 
 
• Developing approaches to examine physiological and therapeutic effects of culture- 
expanded stem cells 
 
In addition to his role as a Professor, Dr. Zandstra is interested in innovation and the 
process by which fundamental research (especially in cell manufacturing and process 
development) can be catalyzed and translated for health and economic impact. Some of 
these efforts are manifest in his role as co-founder and Chief Scientific Officer at CCRM 
(www.ccrm.ca). 
 
CCRM is a Canadian, federally incorporated, not-for-profit organization supporting the 
development of foundational technologies that accelerate the commercialization of 
stem-cell-based products and therapies. Over the last 5 years CCRM has grown to 40+ 
employees (>75% PhD level), launched 4 companies, and attracted >$30M in industry 
funding. Peter has also participated in the founding of two for-profit companies 
(Insception Lifebank and ExCellThera), and is a scientific advisor for a number of 
others, including Silvercreek Pharmaceuticals. ExCellThera, launched in 2015, is a 
clinical stage company that focuses on the development of technologies for robust and 
cost effective blood-stem-cell-based therapies for leukemia and other blood diseases. 
 
Peter is a spectacular teacher and scientist. His scientific accomplishments set the bar 
high for the field. He has the novel ideas and inventiveness to come up with entirely 
new concepts, as well as the intelligence and drive to carry them through to fruition. 
Few laboratories are having more impact on the field. 
 
----------------------------- 
This award recognizes outstanding contributors to the development and 
commercialization of cell-based therapies. Past recipients include Bob Nerem (2014) 
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Sunday, January 15, 2017 
 
16:00 – 19:00 Conference check-in (Bayview Foyer) 
 
18:00 – 18:10 Welcome to conference 
Conference Chairs:  Tom Brieva (Celgene Cellular Therapeutics)                               
Bill Miller (Northwestern University) 
Chris Mason (University College London) 
ECI Liaison:  Barry Buckland  
 
18:10 – 18:40 Poster snapshots 
Session Chairs: Corinne Hoesli (McGill University)  
Eytan Abraham (Lonza) 
 
18:40 – 18:45 Introduction to Plenary 1 
Tom Brieva (Celgene Cellular Therapeutics), ISCT Process and Product 
Development Subcommittee 
 
18:45 – 19:45 Plenary 1 
Moving off-the-shelf into patients; development of pluripotent cell-based 
immunotherapeutics 
Stewart Abbot, Fate Therapeutics, USA 
 
19:45 – 21:00 Dinner 
 





 Technical sessions will be in the Bayview Ballroom. Poster Sessions will be in the Regatta Pavilion. 
 Breakfasts and dinners will be in the Regatta Pavilion. Lunches will be on the Bayview/Sunset 
Terrace.  
 Audiotaping, videotaping and photography of presentations are prohibited. 
 Speakers – Please have your presentation loaded onto the conference computer prior to the session 
start (preferably the day before). 
 Speakers – Please leave at least 3-5 minutes for questions and discussion. Please do not smoke at 
any conference functions. 
 Turn your mobile telephones to vibrate or off during technical sessions. 
 Please write your name on your program so that it can be returned to you if lost or misplaced. 
 After the conference, ECI will send an updated participant list to all participants. Please check your 
listing now and if it needs updating, you may correct it at any time by logging into your ECI account. 
 
Monday, January 16, 2017 
 
07:00 – 08:30 Breakfast buffet 
 
08:30 – 11:35 Session 1: Novel technologies for cell therapy manufacturing 
Sponsored by Panasonic Healthcare Corporation of North America 
Session Chairs: Jamie Piret (University of British Columbia) 
Jon Rowley (RoosterBio) 
 
08:30 – 08:35 Introduction 
 
08:35 – 09:00 Acoustic cell washing and Raman spectroscopy to address cell 
therapy bioprocess challenges 
Jamie Piret, University of British Columbia, Canada 
 
09:00 – 09:25 Bespoke cell therapy manufacturing platforms - A contradiction in terms? 
Eytan Abraham, Lonza, USA, ISCT Process and Product Development Subcommittee 
 
09:25 – 09:45 DMSO-free method of preserving mesenchymal stem cells (MSCs) that retains 
high levels of post thaw function 
Katie Pollock, University of Minnesota, USA 
 
09:45 – 10:05 Incorporating quality in engineered tissues using bottom-up niche assemblies 
Ioannis Papantoniou, KU Leuven, Belgium 
 
10:05 – 10:25 Xeno-free production and recovery of human pluripotent stem cells 
using synthetic dissolvable microcarriers 
Maria Margarida Diogo, University of Lisbon, Portugal 
 
10:25 – 10:55 Coffee break 
 
10:55 – 11:15 Magnetic ratcheting cytometry towards manufacturing scale separations of “best 
in class” 
Coleman T. Murray, University of California, Los Angeles, USA 
 
11:15 – 11:35 Development of a high-dose engineered TCR T cell manufacturing process 
using automated semi-continuous perfusion bioreactors 
Kenny Choi, Kite Pharma, USA 
 
11:35 – 11:40 Introduction to Plenary 2 
Bill Miller (Northwestern University) 
 
11:40 – 12:40 Plenary 2 
Design of novel materials to regulate stem and progenitor cell expansion 
and differentiation 
Kristi Anseth, University of Colorado, USA 
 
12:45 – 14:15 Lunch 
 
14:15 – 16:25 Networking and free time (includes industrial promotion session) 
 
15:45 – 16:15 Industrial promotion session  
Session Chairs: Tom Brieva (Celgene Cellular Therapeutics)                   
Bill Miller (Northwestern University) 
 
15:45 – 16:00 Enabling technology for scalable manufacturing of cell therapy products 
 Brian Lee, PBS Biotech, Inc., USA 
 
 
Monday, January 16, 2017 (continued) 
 
16:00 – 16:15 Total quality approach to cell incubation and processing / scale-up & scale-out 
 Kevin Murray, BioSpherix, Ltd., USA  
 
16:25 – 18:00 Session 2: Collaborating with regulatory agencies to define the landscape for 
emerging cell-based therapies – challenges and lessons learned 
Session Chairs:  Bernadette Keane (Keane Consulting)  
Mohammad Heidaran (US Food and Drug Administration) 
 
16:25 – 16:40 Industry challenges and questions for regulatory authorities 
Bernadette Keane, Keane Consulting, USA 
 
16:40 – 17:05 Cell therapy product manufacturing considerations 
Mohammad Heidaran, US Food and Drug Administration, USA 
 
17:05 – 17:30 Regulatory aspects of manufacturing and control of genetically modified cells 
Matthias Renner, Paul Ehrlich Institute, Germany 
 
17:30 – 18:00 Panel discussion with questions from the audience 
Topic 1: How to better define the cell-based product CQA and CPP? 
Topic 2: Challenges of establishing reliable assays which could be useful in 
measuring product potency. 
Topic 3: How to deal with manufacturing changes including automation 
introduced during late stages of the product development cycle? 
Topic 4: Approaches for establishing product comparability. 
Topic 5: Challenges of establishing control over the source materials and 
ancillary materials. 
Topic 6: What is the relationship between the lot release tests and the drug 
product CQA? 
Topic 7: Importance of establishing and distinguishing drug substance from drug 
product. 
 
18:00 – 19:00 Poster snapshots 
Session Chairs: Corinne Hoesli (McGill University)  
Eytan Abraham (Lonza) 
 
19:00 – 20:30 Dinner 
 
20:30 – 22:00 Poster session with dessert and social hour 
Sponsored by MilliporeSigma 
   
 
Tuesday, January 17, 2017 
 
07:00 – 08:30 Breakfast buffet 
 
08:30 – 10:35 Session 3: Product characterization and potency 
Session Chairs: Anne Plant (National Institute of Standards and Technology) 
Chris Wiwi (Celgene) 
 
08:30 – 08:35 Introduction 
 
08:35 – 09:00 A systems approach for CAR T cell therapy product characterization 
Sadik Kassim, Novartis, USA 
 
09:00 – 09:25 Implications of the CAACB virus contamination in biomanufacturing project for 
cell therapy manufacturers 
Paul Barone, Massachusetts Institute of Technology, USA 
 
09:25 – 09:45 Novel assays for immunotherapy product characterization and 
potency measurement 
Damian Marshall, Cell and Gene Therapy Catapult, UK 
 
09:45 – 10:05 Metabolism regulation of phenotypic and therapeutic properties of 
human mesenchymal stem cells 
Teng Ma, Florida State University, USA 
 
10:05 – 10:25 Evaluating the quality of cell counting measurements using experimental 
design and statistical analysis 
Sumona Sarkar, National Institute of Standards and Technology, USA 
 
10:25 – 10:55 Coffee break 
 
10:55 – 13:00 Session 4: Manufacturing CAR T cells and other cancer immunotherapies: 
challenges and progress 
Sponsored by Sartorius Group North America 
Session Chairs: David Stroncek (National Institutes of Health)  
                          Marianna Sabatino (Kite Pharma) 
 
10:55 – 11:00 Introduction 
 
11:00 – 11:25 Optimizing CAR T cell therapy for hematologic malignancies 
Terry Fry, National Institutes of Health, USA 
 
11:25 – 11:50  Production of anti-CD19 CAR T cells to support multicenter trials evaluating   
                                        KTE- C19 in B cell malignancies 
                                       Marianna Sabatino, Kite Pharma, USA 
 
11:50 – 12:15  Removal of myeloid cells from autologous leukocytes used for chimeric 
antigen receptor (CAR) T cell manufacturing improves final product 
consistency and yields 
David Stroncek, National Institutes of Health, USA 
 
12:15 – 12:40  Considerations and challenges associated with manufacturing autologous  
                                        cellular therapies such as Car T Cells 
Dawn Maier, bluebird bio, USA 
 
12:40 – 13:00 Cost effective manufacturing strategies for feasible commercialization of 
CAR T-cell products 
Tania Chilima, University College London, UK 
 
Tuesday, January 17, 2017 (continued) 
 
13:00 – 14:45 Lunch, networking and free time 
 
14:45 – 17:45 Session 5: Gene editing, vector production, synthetic biology, and genetic 
modification of cells 
Session Chairs: Paula Alves (Instituto de Biologia Experimental e Tecnológica) 
Robert Kutner (Rocket Pharma) 
 
14:45 – 14:50 Introduction 
 
14:50 – 15:15 Gene therapy for inherited blood diseases, from viral vectors to gene editing 
Fulvio Mavilio, Genethon, France 
 
15:15 – 15:40 Challenges and solutions to quality GMP supply of AAV vectors 
Anandita Seth, Lonza, USA 
 
15:40 – 16:05 Translation of pseudotyped HIV-1-based lentiviral vectors for clinical  
                                       applications 
Robert Kutner, Rocket Pharma, USA 
 
16:05 – 16:35 Coffee break 
 
16:35 – 17:00 Altering, improving, and defining the specificities of CRISPR-Cas nucleases 
Ben Kleinstiver, Joung Lab, Harvard University, USA 
 
17:00 – 17:25 Engineering red blood cells for therapeutic function 
Robert Deans, Rubius Therapeutics, USA 
 
17:25 – 17:45 Exosomes for regenerative medicine – manufacturing challenges and potential 
applications 
Ivan W all, University College London, UK 
 
18:00 Buses depart for Stone Brewing World Bistro 
 
18:15 – 21:15 Social hour, networking, and grazing dinner at Stone Brewing World Bistro 
(buses will return to the Hyatt beginning at 19:30 and ending at 21:15) 
 
 
Wednesday, January 18, 2017 
 
  07:00 – 08:30 Breakfast buffet 
 
08:30 – 11:55 Session 6: Upstream and downstream process characterization, scale-
up, comparability, and in-line process monitoring 
Sponsored by Pall Life Sciences 
Session Chairs: Joaquim Cabral (University of 
Lisbon) Fran Meacle (Johnson & 
Johnson) 
 
08:30 – 08:35 Introduction 
 
08:35 – 09:00 Metabolomics and the role of metabolism in stem cell bioprocessing 
Sakis Mantalaris, Imperial College London, UK 
 
09:00 – 09:25 Process scale-up and characterization for a cardiac-derived cell therapy 
Rachel Smith, Capricor Therapeutics, USA 
 
09:25 – 09:45 Clinical scale manufacturing of autologous insulin-producing liver cells for 
the treatment of diabetes 
Rachel Legmann, Pall Life Sciences, USA 
 
09:45 – 10:05 Characterization and optimization of the nanobridge system for hESC 
suspension cultures 
Peter Gray, University of Queensland, Australia 
 
10:05 – 10:35 Coffee break 
 
10:35 – 10:55 High density ex vivo expansion of stem cell aggregates in stirred perfusion 
bioreactors 
Ernesto Scibona, ETH Zurich, Switzerland 
 
10:55 – 11:15 Interactive visualization of cell expansion process performance 
Toon Lambrechts, KU Leuven, Belgium 
 
11:15 – 11:35 Process and equipment scale-up of controlled-rate freezing in cell therapy 
Jonathan Rubin, Janssen R&D, USA 
 
11:35 – 11:55 Bioprocess integration for human mesenchymal stem cells: from up to 
downstream processing scale-up to cell proteome characterization 
Margarida Serra, Instituto de Biologia Experimental e Tecnológica, Portugal 
 
12:00 – 15:30 Lunch on your own, networking and free time 
 
15:30 – 15:35 Introduction to Award Lecture 
Bill Miller (Northwestern University) 
 
15:35 – 16:35 Scale-up and Manufacturing of Cell-Based Therapies Award Lecture 
Sponsored by Pfizer and ECI 
Engineering stem cell fate for drug development and therapy 
Peter Zandstra, University of Toronto, Canada 
 








Wednesday, January 18, 2017 (continued) 
 
17:05 – 18:35 Session 7: Bioprocess modeling – the road to informed decision-making 
for successful commercialization 
Session Chairs: Dolores Baksh (GE Healthcare), ISCT Commercialization Committee 
Suzanne S. Farid (University College London), ISCT Business 
Models and COGs Subcommittee 
 
17:05 – 17:10 Introduction 
 
17:10 – 17:30 Decision support tools for cost-effective bioprocess design in the cell therapy 
sector 
Michael Jenkins, University College London, UK 
 
17:30 –17:50 Utilizing simulation and optimization techniques to evaluate different CAR T cell 
therapy manufacturing paradigms 
Jon Gunther, Juno Therapeutics, USA 
 
17:50 – 18:10 Dynamic mechanistic modelling and controlled growth factor delivery for 
optimization of scalable haematopoietic cell processing 
Robert Thomas, Loughborough University, UK 
 
18:10 – 18:35 Panel discussion with questions from the audience 
  Topic 1: How do we get management buy-in for modeling and when is the 
best time to introduce modeling in the development pathway? 
  Topic 2: What criteria do we consider and optimize for when designing new 
cell therapy processes? 
 Topic 3: Will the cell therapy sector reach the point where process models 
enable process control? 
 
18:35 – 19:00 Break  
 
19:00 – 21:00 Banquet 
 
21:00 – 22:30 Social hour with dessert 
 
Thursday, January 19, 2017 
 
06:30 – 08:00                Breakfast buffet 
 
  08:00 – 08:10               Introduction to the ISCT Process and Product Development Subcommittee and  
                                        Plenary 3  
                                        Dominic M. Clarke (Charter Medical)  
 Eytan Abraham (Lonza) 
 ISCT Process and Product Development Subcommittee                                         
 
08:10 – 09:10 Plenary 3 
Sponsored by the ISCT Process and Product Development Subcommittee 
How to use computational fluid dynamics in the development of cell therapeutics 
Valentin Jossen, Eibl Lab, Zurich University of Applied Science, Switzerland 
 
09:10 – 10:05  Session 8: From method to manufacturing, ramping-up for commercial production 
 Sponsored by Eppendorf AG 
 Session Chairs: Nick Timmins (CCRM)    
                           Greg Russotti (Celgene Cellular Therapeutics) 
 
09:10 – 09:15 Introduction 
 
09:15 – 09:40 A penny today or a dollar tomorrow – early stage development for future success 
Nick Timmins, CCRM, Canada 
 
09:40 – 10:05 Cell Therapy Manufacturing: It's about "TIME" 
Donald Powers, Janssen, USA 
 
 
10:05 – 10:10 Introduction to Plenary 4 
Tom Brieva (Celgene Cellular Therapeutics) 
 
10:10 – 11:10 Plenary 4 
CAR-T manufacturing: delivering on the promise of a transformational therapy 
Greg Russotti, Celgene Cellular Therapeutics, USA 
 
11:10 – 11:35 Coffee break 
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1.  Process development approaches for expansion of adherent stem cells in 
microcarrier-based bioreactor culture 
Kara Levine, MilliporeSigma, USA 
 
2.  Scale-out of massively parallel patient-specific cell cultures with a modified 
transportable conditioned cell culture chamber 
Alicia D. Henn, BioSpherix, USA 
 
3.  Umbilical cord matrix derived-mesenchymal stem cell production in microcarrier-
based culture systems 
Ana Fernandes-Platzgummer, Instituto Superior Técnico, Universidade de Lisboa, Portugal 
 
4.  Microfluidic tools and high-content imaging for cell therapy bioprocessing 
Ana Valinhas, University College London, United Kingdom 
 
5.  Characterization of a 3D matrix bioreactor for scaled production of human 
mesenchymal stem cells 
Andrew B. Burns, Keck Graduate Institute, USA 
 
6.  Development of a chemically defined, animal-component-free ex vivo expansion 
process for activated human T cells 
Annie Ngo, Irvine Scientific, USA 
 
7.  Characterisation and process verification studies in a miniature bioreactor used as a 
predictive tool to scale-up an industrial process 
Asma Ahmad, University College London, United Kingdom 
 
8.  A novel acoustic cell processing platform for cell concentration and washing 
Bart Lipkens, FloDesign Sonics, USA 
 
9.  Enginnering cardiac tissue using human induced pluripotent stem cell derivatives: 
Proteomic characterization of co-cultures of cardiomyocytes and endothelial cells 
Bernardo Abecasis, IBET, Portugal 
 
10.  Expansion of 3D human induced pluripotent stem cell aggregates in bioreactors: 
Bioprocess intensification and scaling-up approaches 
Bernardo Abecasis, IBET, Portugal 
 
11.  Computational fluid dynamic modeling of 100ml and scaled-down 10ml stirred 
suspension bioreactors enables prediction of embryonic stem cell characteristics 
Breanna Shalyn Borys, University of Calgary, Canada 
 
12.  New paradigm of scalable manufacturing for allogeneic cell therapy products 
Brian Lee, PBS Biotech, Inc., USA 
 
13.  Development of a scale-down approach to the scalable culture of induced Pluripotent 
Stem Cells on microcarriers using single-use Vertical-Wheel™ bioreactors under 
xeno-free conditions 
Carlos A. V. Rodrigues, Instituto Superior Técnico, Universidade de Lisboa, Portugal 
 
14.  Impact of high extracellular lactate on induced pluripotent stem cell metabolism and 
pluripotency 
Daniel Odenwelder, Clemson University, USA 
 
15.  Optimization of a scalable single-use manufacturing platform for expansion of high 
quality human mesenchymal stem cells 
David Splan, Pall Life Sciences, USA 
 
16.  Enabling human pluripotent stem cell derived megakaryocyte manufacture 
Elizabeth Cheeseman, Loughborough University, United Kingdom 
 
17.  Optimized media and workflow for the expansion of human pluripotent stem cells as 
aggregates in suspension 
Eric J. Jervis, STEMCELL Technologies, Canada 
 
18.  Combined with #48 as # 74 
 
19.  Scaled-up expansion of equine cord blood mesenchymal stem cells (MSCs) from 
stirred suspension bioreactors to 100mL computer controlled stirred suspension 
bioreactors using computational fluid dynamic modeling 
Erin Roberts, University of Calgary, Canada 
 
20.  Maintenance of stemness and optimization of differentiation potentials during in vitro 
expansion of human adipose-derived stem cells 
EunAh Lee, Kyung Hee University, South Korea 
 
21.  Appraisal of microcarrier suspension dynamics in shaken bioreactors 
Gregorio Rodriguez, University College London, United Kingdom 
 
22.  Large-scale stem cell production system by newly designed bioreactor 
Hideaki Kagawa, FUJIFILM Corporation, Japan 
 
23.  Optimized process for regulatory T cell activation and expansion using Dynabeads™ 
Treg CD3/CD28 for clinical applications 
Hui Zhang, Thermo Fisher Scientific, Norway 
 
24.  Development of downstream processing options for the commercial scale purification 
of stem cell derived exosomes 
Ivano L. Colao, University College London, United Kingdom 
 
25.  Economics and quality attributes of hMSC production in xeno-free bioprocessing 
media 
Jon Rowley, RoosterBio, USA 
 
26.  Improving production of retroviral vector from Pg13 cells for T cell therapy 
Joseph Shiloach, NIDDK/NIH, USA 
 
27.  Manufacturing solutions for robust cell therapy expansion and harvest 
Sandhya Punreddy, MilliporeSigma, USA 
 
28.  Development of microchannel emulsification as a novel cell encapsulation technology 
Karen E. Markwick, McGill University, Canada 
 
29.  A mechanistic model of erythroblast growth inhibition: Optimising red blood cell 
manufacture 
Katie Glen, Loughborough University, United Kingdom 
 
 
30.  TRPV-1 activation through thermal and agonist treatment in the process of scalable 
cardiac differentiation and tissues fabrication is the novel strategy to eliminate 
undifferentiated iPS cells in the bioengineered cardiac tissues 
Katsuhisa Matsuura, Tokyo Women's Medical University, Japan 
 
31.  Assay automation towards the commercialization of cell therapies 
Kruti H. Shah, Celgene, USA 
 
32.  Industrially-relevant examples using a data analytics strategy to effectively address 
complex performance challenges 
Lisa Graham, Alkemy Innovation, Inc., USA 
 
33.  Opportunities for applying biomedical production and manufacturing methods to the 
development of the clean meat industry 
Liz Specht, Good Food Institute, USA 
 
34.  Rapid human T cell expansion using gas-permeable bags in the Eppendorf New 
BrunswickTM S41i CO2 incubator shaker 
Ma Sha, Eppendorf Inc., USA 
 
35.  Establishing the design space of a filtration-based operation for the concentration of 
human pluripotent stem cells 
Manuel JT Carrondo, iBET/FCT-NOVA, Portugal 
 
36.  Characterization and fractionation in Aqueous Two-Phase Systems of site-specific 
PEGylated antibodies: Targeting stem cell separation 
Marco Rito-Palomares, Tecnológico de Monterrey, Mexico 
 
37.  Unveiling human Cardiac Stem Cells regenerative potential in Ishemia/Reperfusion 
Injury 
Margarida Serra, iBet/ ITQB NOVA, Portugal 
 
38.  Effective hypothermic storage of human pluripotent stem cell-derived cardiomyocytes 
compatible with global distribution of cells for clinical applications and toxicology 
testing 
Margarida Serra, iBET, Portugal 
 
39.  Improving production and maturation of cardiomyocytes derivedfrom human 
pluripotent stem cells: An “-Omics” driven approach 
Margarida Serra, iBET, Portugal 
 
40.  Development and optimization of animal origin-free, serum-free media for human treg 
manufacturing 
Maria de los Angeles Torres-Castillo, Thermo Fisher Scientific, USA 
 
41.  Scaling up a chemically-defined aggregate-based suspension culture system for 
neural commitment of human pluripotent stem cells 
Maria Margarida Diogo, Instituto Superior Técnico, Universidade de Lisboa, Portugal 
 
42.  Impact of the hydrodynamic environment on cardiomyocyte differentiation of iPSC 
Martina Micheletti, University College London, United Kingdom 
 
43.  Comprehensive cell manufacturing system based on flexible modular platform 
Masahiro Kino-oka, Osaka University, Japan 
 
44.  The development of scalable bioreactor series for human iPS cell stirred suspension 
culture 
Masanori Wada, ABLE Corporation, Japan 
 
45.  Designing a banking scale of human induced pluripotent stem cells based on 
suspension time-dependent quality variations in filling and cryopreservation 
processes 
Masashi Kagihiro, Sumitomo Dainippon Pharma Co., Ltd., Japan 
 
46.  Economic and operational appraisal of an allogeneic CAR T-cell bioprocess 
Michael J. Jenkins, University College London, United Kingdom 
 
47.  Control of starting material and final product administration of cellular therapies 
Nayyereh Rajaei, Celgene, USA 
 
48.  Combined with #18 as # 74 
 
49.  Application of quality by design concepts and automation to improve manufacturing 
process consistency of development and clinical-stage cell therapies 
Peter David Mitchell, Loughborough University, United Kingdom 
 
50.  Process development of human mesenchymal stem cell microcarrier culture using an 
automated high-throughput microbioreactor 
Qasim Rafiq, Aston University, United Kingdom 
 
51.  Experimental and Computational Fluid Dynamics study of microcarrier suspension 
during the cultivation of Mesenchymal Stem Cells in an ambr250 bioreactor 
Qasim Rafiq, Aston University, United Kingdom 
 
52.  Investigating the requirement for dual cell co-culture platforms in creating 
regenerative cell therapies for CNS injury 
Rachael C. Wood, University College London, United Kingdom 
 
53.  Determination of an optimal formulation for CAR-T Cells: Cryopreservation studies 
using model T-Cells 
Rachel N. Witts, Pfizer, USA 
 
54.  Albumin in cell culture media – An examination of quality and function 
Randall W. Alfano, InVitria, USA 
 
55.  Scalable and controlled presentation of surface immobilised factors from the bone 
marrow niche for hematopoietic cell expansion 
Rebecca Moore, Loughborough University, United Kingdom 
 
56.  Development of a cost efficient platform for the industrial manufacturing of pluripotent 
stem cell derived products for cell therapy: Cell expansion is the starting point 
Jahid Hasan, The Cell and Gene Therapy Catapult, United Kingdom 
 
57.  An alternative methodology for a quantitative flow-based cell-mediated in vitro 
cytotoxicity assay to evaluate immune cell potency 
Sherry Zhou, Celgene Corporation, USA 
 
58.  WITHDRAWN 
 
 
59.  Application of the migratory nature of human mesenchymal stem cells to optimise 
microcarrier-based expansion processes 
Steven Ruck, Loughborough University, United Kingdom 
 
60.  High density culture of human induced pluripotent stem cells through the refinement 
of medium by dialysis in suspension 
Suman Chandra Nath, Osaka University, Japan 
 
61.  NIST and FDA collaboration on standards development activities and laboratory 
programs supporting translation of regenerative medicine products 
Sumona Sarkar, NIST, USA 
 
62.  A method for estimating capital investment and facility footprint of cell therapy 
facilities 
Tania Doroteia Pereira Chilima, University College London, United Kingdom 
 
63.  Aggregation kinetics of human mesenchymal stem cells under wave motion 
Teng Ma, Florida State University, USA 
 
64.  Dissolvable microcarriers for efficient cell production and recovery 
Todd Sciortino, Corning Incorporated, USA 
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